1:
NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models.
Jensen MR, Schoepfer J, Radimerski T, Massey A, Guy CT, Brueggen J, Quadt C, Buckler A, Cozens R, Drysdale MJ, Garcia-Echeverria C, Chène P.
Breast Cancer Res. 2008;10(2):R33. Epub 2008 Apr 22.
PMID: 18430202 [PubMed - indexed for MEDLINE]
Related Articles Free article in PMC
2:
NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis.
Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, Valenti M, Patterson L, de Haven Brandon A, Gowan S, Boxall F, Aherne W, Rowlands M, Hayes A, Martins V, Urban F, Boxall K, Prodromou C, Pearl L, James K, Matthews TP, Cheung KM, Kalusa A, Jones K, McDonald E, Barril X, Brough PA, Cansfield JE, Dymock B, Drysdale MJ, Finch H, Howes R, Hubbard RE, Surgenor A, Webb P, Wood M, Wright L, Workman P.
Cancer Res. 2008 Apr 15;68(8):2850-60.
PMID: 18413753 [PubMed - indexed for MEDLINE]
Related Articles
3:
4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer.
Brough PA, Aherne W, Barril X, Borgognoni J, Boxall K, Cansfield JE, Cheung KM, Collins I, Davies NG, Drysdale MJ, Dymock B, Eccles SA, Finch H, Fink A, Hayes A, Howes R, Hubbard RE, James K, Jordan AM, Lockie A, Martins V, Massey A, Matthews TP, McDonald E, Northfield CJ, Pearl LH, Prodromou C, Ray S, Raynaud FI, Roughley SD, Sharp SY, Surgenor A, Walmsley DL, Webb P, Wood M, Workman P, Wright L.
J Med Chem. 2008 Jan 24;51(2):196-218. Epub 2007 Nov 20.
PMID: 18020435 [PubMed - indexed for MEDLINE]
Related Articles
5:
Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma.
Stühmer T, Zöllinger A, Siegmund D, Chatterjee M, Grella E, Knop S, Kortüm M, Unzicker C, Jensen MR, Quadt C, Chène P, Schoepfer J, García-Echeverría C, Einsele H, Wajant H, Bargou RC.
Leukemia. 2008 Aug;22(8):1604-12. Epub 2008 May 15.
PMID: 18480838 [PubMed - indexed for MEDLINE]
Related Articles
6:
Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer.
Srirangam A, Mitra R, Wang M, Gorski JC, Badve S, Baldridge L, Hamilton J, Kishimoto H, Hawes J, Li L, Orschell CM, Srour EF, Blum JS, Donner D, Sledge GW, Nakshatri H, Potter DA.
Clin Cancer Res. 2006 Mar 15;12(6):1883-96.
PMID: 16551874 [PubMed - indexed for MEDLINE]
Related Articles
7:
SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers.
Chandarlapaty S, Sawai A, Ye Q, Scott A, Silinski M, Huang K, Fadden P, Partdrige J, Hall S, Steed P, Norton L, Rosen N, Solit DB.
Clin Cancer Res. 2008 Jan 1;14(1):240-8.
PMID: 18172276 [PubMed - indexed for MEDLINE]
Related Articles
10:
Identification of new biomarkers for clinical trials of Hsp90 inhibitors.
Zhang H, Chung D, Yang YC, Neely L, Tsurumoto S, Fan J, Zhang L, Biamonte M, Brekken J, Lundgren K, Burrows F.
Mol Cancer Ther. 2006 May;5(5):1256-64.
PMID: 16731758 [PubMed - indexed for MEDLINE]
Related Articles
11:
Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program.
Smith MA, Morton CL, Phelps DA, Kolb EA, Lock R, Carol H, Reynolds CP, Maris JM, Keir ST, Wu J, Houghton PJ.
Pediatr Blood Cancer. 2008 Jul;51(1):34-41.
PMID: 18260120 [PubMed - indexed for MEDLINE]
Related Articles
15:
Stereospecific antitumor activity of radicicol oxime derivatives.
Soga S, Sharma SV, Shiotsu Y, Shimizu M, Tahara H, Yamaguchi K, Ikuina Y, Murakata C, Tamaoki T, Kurebayashi J, Schulte TW, Neckers LM, Akinaga S.
Cancer Chemother Pharmacol. 2001 Dec;48(6):435-45.
PMID: 11800023 [PubMed - indexed for MEDLINE]
Related Articles
16:
Structural basis for depletion of heat shock protein 90 client proteins by deguelin.
Oh SH, Woo JK, Yazici YD, Myers JN, Kim WY, Jin Q, Hong SS, Park HJ, Suh YG, Kim KW, Hong WK, Lee HY.
J Natl Cancer Inst. 2007 Jun 20;99(12):949-61. Epub 2007 Jun 12.
PMID: 17565155 [PubMed - indexed for MEDLINE]
Related Articles
18:
Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
Kasibhatla SR, Hong K, Biamonte MA, Busch DJ, Karjian PL, Sensintaffar JL, Kamal A, Lough RE, Brekken J, Lundgren K, Grecko R, Timony GA, Ran Y, Mansfield R, Fritz LC, Ulm E, Burrows FJ, Boehm MF.
J Med Chem. 2007 Jun 14;50(12):2767-78. Epub 2007 May 8.
PMID: 17488003 [PubMed - indexed for MEDLINE]
Related Articles
19:
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.
Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chène P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, García-Echeverría C.
Mol Cancer Ther. 2008 Jul;7(7):1851-63. Epub 2008 Jul 7.
PMID: 18606717 [PubMed - indexed for MEDLINE]
Related Articles